
NeoGenomics, Inc. – NASDAQ:NEO
NeoGenomics stock price today
NeoGenomics stock price monthly change
NeoGenomics stock price quarterly change
NeoGenomics stock price yearly change
NeoGenomics key metrics
Market Cap | 2.10B |
Enterprise value | 2.28B |
P/E | -15.24 |
EV/Sales | 4.48 |
EV/EBITDA | -24.61 |
Price/Sales | 3.80 |
Price/Book | 1.94 |
PEG ratio | N/A |
EPS | -0.65 |
Revenue | 610.66M |
EBITDA | -8.54M |
Income | -84.23M |
Revenue Q/Q | 13.86% |
Revenue Y/Y | 15.26% |
Profit margin | -28.3% |
Oper. margin | -30.04% |
Gross margin | 36.86% |
EBIT margin | -30.04% |
EBITDA margin | -1.4% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNeoGenomics stock price history
NeoGenomics stock forecast
NeoGenomics financial statements
Jun 2023 | 146.91M | -24.33M | -16.56% |
---|---|---|---|
Sep 2023 | 151.95M | -18.51M | -12.19% |
Dec 2023 | 155.55M | -14.32M | -9.21% |
Mar 2024 | 156.24M | -27.06M | -17.32% |
Sep 2025 | 183.58M | 4.91M | 2.68% |
---|---|---|---|
Oct 2025 | 181.87M | 5.60M | 3.08% |
Dec 2025 | 188.81M | 9.53M | 5.05% |
Mar 2026 | 180.19M | 3.22M | 1.79% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 1695108000 | 738.91M | 43.59% |
---|---|---|---|
Sep 2023 | 1678241000 | 730.81M | 43.55% |
Dec 2023 | 1681229000 | 739.69M | 44% |
Mar 2024 | 1640339000 | 716.92M | 43.71% |
Jun 2023 | -1.54M | 14.94M | 64K |
---|---|---|---|
Sep 2023 | -5.49M | 20.82M | 1.84M |
Dec 2023 | 17.78M | 17.19M | 1.27M |
Mar 2024 | -25.91M | 14.52M | 816K |
NeoGenomics alternative data
Aug 2023 | 2,100 |
---|---|
Sep 2023 | 2,100 |
Oct 2023 | 2,100 |
Nov 2023 | 2,100 |
Dec 2023 | 2,100 |
Jan 2024 | 2,100 |
Feb 2024 | 2,100 |
Apr 2024 | 2,100 |
May 2024 | 2,100 |
Jun 2024 | 2,100 |
Jul 2024 | 2,100 |
NeoGenomics other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 0 | 2587 |
Mar 2024 | 0 | 6112 |
May 2024 | 0 | 1049 |
Aug 2024 | 0 | 1040 |
Nov 2024 | 0 | 5175 |
Quarter | Transcript |
---|---|
Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 20 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Douglas M. Brown (1970) Chief Strategy & Corporation Devel. Officer | $677,650 |
GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing
NeoGenomics: What Lies Ahead
NeoGenomics: At A Key Inflection Point In Growth Route
Exact Sciences Up 25% YTD: Here Is What To Expect In 2023
Sema4: Restructuring Plan Figures Don't Add Up
NeoGenomics: What The Leadership Shuffle Means
NeoGenomics: Too Early To Celebrate
Invitae: This Turnaround Could Be Painful
NeoGenomics: Market Punishment Continues, But Looks Justified
-
What's the price of NeoGenomics stock today?
One share of NeoGenomics stock can currently be purchased for approximately $6.19.
-
When is NeoGenomics's next earnings date?
Unfortunately, NeoGenomics's (NEO) next earnings date is currently unknown.
-
Does NeoGenomics pay dividends?
No, NeoGenomics does not pay dividends.
-
How much money does NeoGenomics make?
NeoGenomics has a market capitalization of 2.10B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 16.07% to 591.64M US dollars.
-
What is NeoGenomics's stock symbol?
NeoGenomics, Inc. is traded on the NASDAQ under the ticker symbol "NEO".
-
What is NeoGenomics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of NeoGenomics?
Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are NeoGenomics's key executives?
NeoGenomics's management team includes the following people:
- Mr. Douglas M. Brown Chief Strategy & Corporation Devel. Officer(age: 55, pay: $677,650)
-
How many employees does NeoGenomics have?
As Jul 2024, NeoGenomics employs 2,100 workers.
-
When NeoGenomics went public?
NeoGenomics, Inc. is publicly traded company for more then 21 years since IPO on 16 Mar 2004.
-
What is NeoGenomics's official website?
The official website for NeoGenomics is neogenomics.com.
-
Where are NeoGenomics's headquarters?
NeoGenomics is headquartered at 9490 NeoGenomics Way, Fort Myers, FL.
-
How can i contact NeoGenomics?
NeoGenomics's mailing address is 9490 NeoGenomics Way, Fort Myers, FL and company can be reached via phone at +239 7680600.
NeoGenomics company profile:

NeoGenomics, Inc.
neogenomics.comNASDAQ
2,100
Medical - Diagnostics & Research
Healthcare
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Fort Myers, FL 33912
CIK: 0001077183
ISIN: US64049M2098
CUSIP: 64049M209